Digestive System Carcinoma — Research

Digestive System Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	13	`("Digestive System Carcinoma"[tiab] OR "Gastrointestinal System Carcinoma"[tiab] OR "Carcinoma of the Gastrointestinal System"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	5	`("Digestive System Carcinoma"[tiab] OR "Gastrointestinal System Carcinoma"[tiab] OR "Carcinoma of the Gastrointestinal System"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	0	`("Digestive System Carcinoma"[tiab] OR "Gastrointestinal System Carcinoma"[tiab] OR "Carcinoma of the Gastrointestinal System"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 19 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (168)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–25 of 168 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
· N Engl J Med · 2019 · PMID 31157963 · validated civic_curation pubmed
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
· Lancet Oncol · 2020 · PMID 32416072 · validated civic_curation pubmed
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
· Lancet · 2010 · PMID 20728210 · validated civic_curation pubmed
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.